JOINT STOCK COMPANY LATVIJAS JŪRAS MEDICĪNAS CENTRS
(Unified registration number: 40003306807)
ANNUAL REPORT FOR THE 12 MONTHS OF 2022
(19th financial year)
PREPARED IN ACCORDANCE WITH THE ‘ACCOUNTING LAW’ AND ‘ANNUAL REPORTS AND CONSOLIDATED ANNUAL REPORTS LAW’ OF THE REPUBLIC OF LATVIA
Riga, 2023
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Content
2
Information on the Company
3
Statement of the Board’s Responsibility
4
Management Report
5 – 6
Remuneration Report
7 - 8
Financial Statements:
Profit and Loss Statement
9
Balance Sheet
10 – 11
Statement of Changes in the Shareholders’ Equity
12
Statement of Cash Flows
13
Note
14 – 28
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Information on the Company
3
Name of the company
Latvijas Jūras medicīnas centrs
Legal status
Joint Stock Company
Number, place and date of registration
40003306807
Riga, 27 August 1996
Re-registered with the Commercial Register
On 27 February 2004 under the unified registration number
4000 330 6807
Core business:
Hospital activities (86.10)
Retail sale of medical and orthopaedic goods in specialised stores (47.74)
Other education n.e.c. (85.59)
General medical practice activities (86.21)
Special medical practice activities (86.22)
Dental practice activities (86.23)
Other human health activities (86.90)
Residential nursing care activities (87.10)
Other residential care activities (87.90)
Other social work activities without accommodation n.e.c. (88.99)
Physical well-being activities (96.04)
Other personal service activities n.e.c. (96.09)
Legal address
Patversmes iela 23
Riga, LV-1005,
Latvia
Largest shareholders
Ilze Birka (17.50%)
Mārtiņš Birks (17.50%)
SIA POM (8.82%)
Guna Švarcberga (10.36%)
Jānis Birks (12.80%)
Adomas Navickas (6.85%)
Names of the Board members, their positions
Jānis Birks – Chairman of the Board
Juris Imaks – Member of the Board
Anatolijs Ahmetovs – Member of the Board
Names of the Council members, their positions
Mārtiņš Birks – Chairman of the Council
Viesturs Šiliņš – Deputy Chairman of the Council
Ineta Gadzjus – Member of the Council
Jevgeņijs Kalējs – Member of the Council
Uldis Osis – Member of the Council
Reporting year
1 January 2022 – 31 December 2017
Name and address of the certified auditor in charge
KPMG Baltics SIACertified Auditor in charge:
License No. 55Rainers Vilāns
Roberta Hirša iela 1Certificate No. 200
Riga, LV-1045,
Latvia
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Statement of the Board’s Responsibility
4
The Board of AS Latvijas Jūras Medicīnas Centrs (hereinafter the Company) is responsible for preparing the financial statements of the Company.
The financial statements on pages 9 to 28 are prepared based on accounting records and source documents and present fairly the financial position of the Company as at 31 December 2022 and the results of its operations, and cash flows for the 12-month period then ended.
The above mentioned financial statement of the Company is prepared in accordance with the ‘Accounting Law’ and ‘Annual Reports and Consolidated Annual Reports Law’ effective in the Republic of Latvia, on a going concern basis. Appropriate accounting policies have been applied on a consistent basis. Prudent and reasonable judgements and estimates have been made by the Management in the preparation of the financial statement.
The management of the Company is responsible for the maintenance of a proper accounting system, safeguarding the Company’s assets, and the prevention and detection of fraud and other irregularities in the Company. The management is also responsible for compliance with laws of the Republic of Latvia.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
 28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Management Report
5
Type of activity
A/S Latvijas Jūras medicīnas centrs (hereinafter - LJMC or the Company) is a certified and advanced private medical facility available to everyone, which consists of Sarkandaugava Ambulatory Healthcare Centre at 23 Patversmes iela, Riga; Central Hospital at 23 Patversmes iela, Riga; Vecmilgravis Hospital and Northern Diagnostics Centre 26 Vecmilgravja 5.linija; Riga, and Vecmīlgrāvis Primary Health Care Centre at 10 Melidas iela, Riga. In 2022, the average number of employees of LJMC was 361. The shares of A/S Latvijas Jūras medicīnas centrs are traded on the Baltic Secondary list of Nasdaq Riga.
As of 5 September 2013, A/S Latvijas Jūras medicīnas centrs has been included on the list of medical facilities approved by the Health Inspectorate of Latvia, which provides medical tourism services, namely, LJMC provides medical tourism services as a reliable partner and this provides an insight into the overall Latvian health care system because the list only includes those healthcare institutions which have been registered with the register of health care institutions for at least 3 years and control has been carried out in the health care institution during the past three years.
LJMC has accredited Clinical Diagnostics Laboratory at 23 Patversmes iela with the Latvian National Accreditation Bureau.
LJMC has signed cooperation agreements with all health insurance companies operating in Latvia.
LJMC has received certificate No. MSC-50-034 issued by Exova BM TRADA confirming compliance of the energy management system with ISO 50001:2018.
Activities in the 12 months of 2022 and further development
The Company’s activities in the 12 months of 2022
In 2022, LJMC continued to provide high-quality medical services and attract new patients. Similar to prior years, also in 2022 LJMC employed excellent doctors from Latvia and competent medical personnel. The highly qualified and professional staff of LJMC is the driving force behind its competitive, high quality examinations and adherence to precautionary standards in the provision of healthcare services, so that interactions between patients and healthcare persons promote accessibility. LJMC is on the official list of providers of medical tourism services maintained by the Health Inspection of the Republic of Latvia. In 2022, LJMC placed information in the medical tourism catalogue created and supported by LIDA. In 2022, the war between Russia and Ukraine has not had a potentially material impact on the Company’s operations. In 2022, LJMC had no business transactions with Russia, Belarus and Ukraine.
In 2022, when providing healthcare services, LJMC demonstrated flexibility in adapting to the regulatory documents issued by the Ministry of Health and their ever changing conditions. Both secondary outpatient and day hospital services, as well as paid healthcare services, were provided to the extent allowed by the regulatory documents, ensuring continuity of operations and stable monitoring of the impact of new events and circumstances.
In 2022, LJMC focussed on the promotion of paid medical services, which helped increase the number of patients living in Latvia and enhanced competitiveness and raised the profile of LJMC.
The Radiology Department in 2021 provided the full range of diagnostic services (magnetic resonance, X-ray examinations and ultrasonography) increasing the amount and quality of services (both state paid services and services paid by patients). PET/CT radiological examinations are available and payable both by private means and state funds.
In order to ensure compliance with the requirements of GDPR, in 2022 LJMC, in cooperation with an independent data protection officer, continued the improvement of documents in compliance with the laws and regulations, continued the improvement of the contract renewal procedure (digital access to medical examinations, use of health information systems, services of insurance companies, communication services), and began the training process for LJMC staff.
In 2022, LJMC signed agreements with the National Health Service for the provision of state paid medical services in the amount provided by the budget for 2022.
In 2022, LJMC continued working on ISO: 9001-2015. In 2022, LJMC received ISO 9001:2015 quality certification in functional diagnostics and radiological diagnostics, in-patient medical rehabilitation and day-care rehabilitation valid until 14 March 2025, and continued updating the hygiene and disinfection plan, and implementing ISO certification in other units of LJMC.
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Management Report
6
Further development of the Company
In order to attract an increasing number of new patients, in 2023 LJMC plans to make investments to introduce innovative solutions for providing medical services, improve staff qualifications and enhance patient service. In 2023, LJMC will also continue to participate in the national policy on the conversion of hospitals into outpatient facilities, by complementing the offer of healthcare services. In 2023, LJMC will continue to make sure that precautionary standards are adhered to in the provision of healthcare services, so that interactions between patients and healthcare persons facilitate accessibility.
Continuing to improve the available services with highly-qualified and professional diagnostics service, LJMC’s Radiology Department, as one of the most modern and innovative cancer diagnostics centre in Eastern Europe, will contribute to the increase in domestic and international patient flow when the safe patient flow is restored.
By attracting patients not only from Latvia and other Baltic countries, but also from other EU countries and offering high-quality medical services, LJMC will increase its competitiveness in the Baltics medical market.
Financial results
In the 12 months of 2022, LJMC performed better than according to the approved budget for 2022. The profit of LJMC is EUR 625 729.
Risk Management
LJMC continues carrying out activities seeking to limit the negative impact of potential financial risks on the financial position of LJMC by implementing a set of control and analysis measures. Financial assets exposed to credit risk are mostly cash, trade receivables and other receivables. Credit risk is managed by LJMC by performing regular debtor control procedures and debt collection measures aiming to identify and solve any problems on a timely basis.
Liquidity risk is managed by LJMC in line with the principle of prudence ensuring that appropriate credit resources are available to cover liabilities as they fall due. Other than operating leases, LJMC does not use borrowed funds.
Subsequent events
No significant subsequent events have occurred in the period from the year-end to the date of these financial statements that would require adjustments to be made to these financial statements and disclosures added to the notes thereto.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Remuneration Report for 2022
7
Introduction
The Remuneration Report of Joint Stock Company “Latvijas Jūras medicīnas centrs” (hereinafter the Company) for 2022 is prepared according to the remuneration policy to members of the Board and Council approved by the decision of the Company’s Shareholders Meeting of 30 November 2020, which is developed on the basis of Directive (EU) 2017/828 of the European Parliament and of the Council of 17 May 2017 as regards the encouragement of long-term shareholder engagement, as well as according to Article 593 of the Financial Instrument Market Law, which introduces the directive.
The Remuneration Report is prepared by the Board and reviewed by the Council of the Company. The Remuneration Report is reviewed and approved by the Shareholders’ Meeting alongside other parts of the Annual Report. According to the Audit Services Law of the Republic of Latvia, a sworn auditor is under the obligation to provide an opinion on whether the information referred to in Section 59.4 of the Financial Instrument Market Law has been included in the Remuneration Report and whether significant non-conformities have been established in the Remuneration Report in relation to the financial information presented in the Annual Report.
The Remuneration Report is published concurrently with the audited annual report of the Company as a separate part of the annual report in Latvian and English on the Company’s website: in section “Remuneration Report”, as well as on the Nasdaq Riga website: http://www.nasdaqbaltic.com.
Remuneration to the Board and Council
The remuneration policy of the Board and Council ensures that in 2022 the Company’s strategy, realization of long-term interests and sustainability, ensuring business continuity, is implemented.
Remuneration to the members of the Council consists only of fixed component of remuneration. In 2022, the following total remuneration was granted and paid to the members of the Council:
Name, surname
Position
Remuneration paid in 2022, EUR
Remuneration paid in 2021, EUR
Remuneration paid in 2020, EUR
Mārtiņš Birks
Chairman of the Council
9 649.79
8 195.76
8 195.76
Ineta Gadzjus
Member of the Council
5 629.07
4 780.92
4 780.92
Viesturs Šiliņš
Member of the Council
5 629.07
4 780.92
4 780.92
Jevgēņijs Kalējs
Member of the Council
5 629.07
4 780.92
4 780.92
Uldis Osis
Member of the Council
5 629.07
4 780.92
4 780.92
Remuneration to the members of the Board consists of a fixed and variable component of remuneration. In 2022, the following total remuneration was granted and paid to the members of the Board:
Name, surname
Position
Remuneration paid in 2022, EUR
Fixed part of remuneration, %
Variable part of remuneration, %
Jānis Birks
Chairman of the Board
90 547
39.97 %
60.03 %
Juris Imaks
Member of the Board
69 218
37.28 %
62.72 %
Anatolijs Ahmetovs
Member of the Board
54 719
47.97 %
52.03 %
Name, surname
Position
Remuneration paid in 2021, EUR
Fixed part of remuneration, %
Variable part of remuneration, %
Jānis Birks
Chairman of the Board
67 445
30.45 %
69.55 %
Juris Imaks
Member of the Board
59 028
31.70 %
68.30 %
Anatolijs Ahmetovs
Member of the Board
48 477
47.20 %
52.80 %
AS Latvijas Jūras medicīnas centrs
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Remuneration Report for 2022
8
Name, surname
Position
Remuneration paid in 2020, EUR
Fixed part of remuneration, %
Variable part of remuneration, %
Jānis Birks
Chairman of the Board
74 315
29.74 %
70.26 %
Juris Imaks
Member of the Board
49 309
35.40 %
64.60 %
Anatolijs Ahmetovs
Member of the Board
42 000
48.82 %
51.18 %
As the variable part of remuneration is linked to net sales, it works as an incentive for the Board to drive the Company’s growth.
Shares or share options were not granted and offered to members of the Board and Council.
No variable part of remuneration was reclaimed from members of the Board and Council.
There were no cases of applying temporary derogations from the remuneration policy.
Section 594, paragraph one, point 3 of the Financial Instrument Market Law requires to report, in a comparable manner, changes that took place in the last five financial years in remuneration paid to members of the Board and Council, performance of the company and average remuneration on a full-time equivalent basis of employees of the company other than members of the Board and Council.
In accordance with Paragraph 66 of the Transitional Provisions of the Financial Instrument Market Law, a comparison of the changes referred to in Section 594, paragraph one, Clause 3 of the Law is provided for at least the period of the last five financial years beginning not later than 1 January 2020.
Remuneration to the Board and Council has not changed significantly during the last 5 years, performance of the company matches its strategic goals, average remuneration on a full-time equivalent basis of employees of the company has increased in line with the overall trends of the labour market.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Financial statements
Profit and Loss Statement for 2022
9
Note
2022
2021
EUR
EUR
1.
Net sales
2
9 700 898
9 363 852
2.
Cost of goods and services
3
(8 926 149)
(8 146 691)
3.
Gross profit
774 749
1 217 161
4.
Administrative expenses
4
(704 751)
(580 253)
5.
Other operating income
5
582 442
247 435
6.
Other operating expenses
6
(26 107)
(3 439)
7.
Profit before income tax
626 333
880 904
8.
Corporate income tax for the reporting year
7
(604)
(645)
9.
Profit of the reporting year
625 729
880 259
Number of shares
 
800 000
800 000
x
Earnings per share (EUR)*
0.78
1.10
* Profit or loss after corporate income tax / average number of shares during the reporting year.
The accompanying notes on pages 14 to 28 form an integral part of these financial statements.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
Chief Accountant
Gunta Kaufmane
28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Balance Sheet as at 31 December 2022
10
Note
31.12.2022
31.12.2021
EUR
EUR
Assets
Non-current assets
I Fixed assets
1.Land, buildings and engineering structures
4 784 474
4 919 770
2. Equipment and machinery
1 401 099
883 062
3. Other fixed assets
92 020
70 196
4. Construction in progress
76 209
70 407
Total fixed assets:
8
6 353 802
5 943 435
Total long term investments:
6 353 802
5 943 435
Current assets
I Stock:
1. Raw materials
9
143 201
156 517
Total stock:
143 201
156 517
II Receivables:
1.Trade receivables
10
82 057
102 008
2. Other receivables
11
585 094
600 254
3. Prepaid expenses
12
9 927
7 270
4. Deferred income
Prepaid expenses
Prepaid expenses
 
4. Prepaid expenses
13
350 787
429 311
Total receivables:
1 027 865
1 138 843
III Cash:
14
1 321 420
1 017 259
Total current assets:
2 492 486
2 312 619
Total assets
8 846 288
8 256 054
The accompanying notes on pages 14 to 28 form an integral part of these financial statements.
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Balance Sheet as at 31 December 2022
11
Note
31.12.2022
31.12.2021
EUR
EUR
Equity and liabilities
Shareholders’ equity:
1. Share capital
15
1 120 000
1 120 000
2. Long-term investment revaluation reserve
16
2 472 973
2 472 973
3. Reserves:
b) reserves provided by the Co-operative’s Statutes
63 819
63 819
4. Retained earnings
 
a) retained earnings carried forward from previous years
        
2 523 721
1 803 462
b) profit of the reporting year
625 729
880 259
Total shareholders’ equity:
6 806 242
6 340 513
Liabilities:
Long term liabilities:
1. Deferred income
19
567 544
628 654
Total long term liabilities:
567 544
628 654
Short-term liabilities:
1. Customer advances
51 606
34 057
2. Accounts payable to suppliers and contractors
447 021
303 198
3 Taxes and compulsory state social security contributions
    
18
217 045
249 572
4. Other liabilities
17
288 058
277 672
5. Deferred income
19
59 092
58 126
6. Accrued liabilities
20
409 680
364 262
Total short term liabilities:
1 472 502
1 286 887
Total liabilities:
2 040 046
1 915 541
Total equity and liabilities
8 846 288
8 256 054
The accompanying notes on pages 14 to 28 form an integral part of these financial statements.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
Chief Accountant
Gunta Kaufmane
28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022
Address: Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Statement of Changes to the Shareholders Equity for 2022
12
Share capital
Long-term investment revaluation reserve
Reserves set in the Company’s statutes
Retained earnings brought forward from previous years
Profit of the reporting year
Total share-holders’ equity
EUR
EUR
EUR
EUR
EUR
EUR
Balance as at 31 December 2020
1 120 000
2 472 973
63 819
1 585 907
273 555
5 516 254
Profit of 2020 transferred to retained earnings of previous years
-
-
-
273 555
(273 555)
-
Dividends for 2017
-
-
-
(56 000)
-
(56 000)
Profit for the reporting year
-
-
-
-
880 259
880 259
Balance as at 31 December 2021
1 120 000
2 472 973
63 819
1 803 462
880 259
6 340 513
Profit of 2021 transferred to retained earnings of previous years
-
-
-
880 259
(880 259)
-
Dividends for 2017
-
-
-
(160 000)
-
(160 000)
Profit for the reporting year
-
-
-
-
625 729
625 729
Balance as at 31 December 2022
1 120 000
2 472 973
63 819
2 523 721
625 729
6 806 242
The accompanying notes on pages 14 to 28 form an integral part of these financial statements.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
Chief Accountant
Gunta Kaufmane
28 April 2023
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Statement of Cash Flows for 2022
13
Note
2022
2021
EUR
EUR
I. Cash flows from operating activities
1. Profit before corporate income tax
626 333
880 904
Adjustments for:
a)impairment of fixed assets
8
427 880
286 644
b)(gain)/loss on disposal of fixed assets
8
5 524
-
2. Profit before adjustments for the effect of changes to current assets and short term liabilities
1 059 737
1 167 548
Adjustments for:
a)decrease/ (increase) in trade receivables
110 978
(817 879)
b)decrease/ (increase) in stock
13 316
(17 961)
c)increase/ (decrease) in accounts payable to suppliers and other liabilities
124 588
87 591
3. Gross cash flows from operating activities
1 308 619
419 299
Corporate income tax
18
(687)
(1 064)
Net cash flows from operating activities
1 307 932
418 235
II. Cash flows used in investing activities
a)purchase of fixed and intangible assets
8
(843 771)
(1 110 016)
6. Net cash flows used in investing activities
(843 771)
(1 110 016)
III. Cash flows from financing activities
a)Dividends paid
(160 000)
(56 000)
7. Net cash flows used in financing activities
(160 000)
(56 000)
Net increase/(decrease) in cash and cash equivalents in the reporting year
304 161
(747 781)
Cash and cash equivalents at the beginning of the year
 
1 017 259
1 765 040
Cash and cash equivalents at the end of the year
14
1 321 420
1 017 259
The accompanying notes on pages 14 to 28 form an integral part of these financial statements.
Chairman of the Board
Jānis Birks
Member of the Board
Juris Imaks
Member of the Board
Anatolijs Ahmetovs
28 April 2023
Chief Accountant
Gunta Kaufmane
THIS DOCUMENT HAS BEEN SIGNED WITH A SECURE ELECTRONIC SIGNATURE AND IT CONTAINS A TIME-STAMP
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
14
(1)Information on the Company’s activities and summary of significant accounting principles
Information on the Company
The legal address AS Latvijas Jūras medicīnas centrs (LJMC or the Company) is 23 Patversmes iela, Riga, Latvia. The Company was registered with the Commercial Register under the common registration number 40003306807. The largest shareholders of the Company are Ilze Birka (17.50%), Mārtiņš Birks (17.50%), Jānis Birks (12.80%), Guna Švarcberga (10.36%), SIA POM (8.82%), Adomas Navickas (6.85%).
The Board comprises Jānis Birks (Chairperson of the Board), Juris Imaks (Board Member) and Anatolijs Ahmetovs (Board Member). The Chairperson of the Council is Mārtiņš Birks, Council Members are Viesturs Šiliņš, Ineta Gadzjus, Jevgēņija Kalējs and Uldis Osis.
The core business of the Company according to NACE rev 2. is Hospital activities (NACE 86.10); Retail sale of medical and orthopaedic goods in specialised stores (47.74); Education n.e.c. (85.59); General medical practice activities (86.21); Special medical practice activities (86.22); Dental practice activities (86.23); Other human health activities (86.90); Residential nursing care activities (87.10); Other residential care activities (87.90); Other social work activities without accommodation n.e.c. (88.99); Physical well-being activities (96.04); Other personal service activities n.e.c. (96.09).
Basis of preparation
The financial statements were prepared in accordance with the ‘Accounting Law’ and the ‘Annual Reports and Consolidated Annual Report Law’ (hereinafter – the Law).
The management believes that the accounting policies used in the preparation of these financial statements are largely consistent with those used last year.
According to Article 3(6) of the Annual Reports and Consolidated Annual Reports Law, the Company applies the requirements of the law applicable to large companies as its transferable securities are included in the regulated market of the Republic of Latvia.
The profit and loss statement was prepared according to the turnover costing method. The cash flow statement was prepared according to the indirect method. The financial statements are prepared on the historical cost basis except for the fixed assets disclosed under Land, buildings and engineering structures – land and buildings, which are measured using a revaluation method.
Accounting principles
The financial statements were prepared in accordance with the following policies:
a)Going concern assumption that the Company will continue as a going concern;
b)Consistent valuation principles with those used in the prior year;
c)Items were valued in accordance with the principle of prudence, i.e.:
The financial statements reflect only the profit generated to the balance sheet date;
all incurred liabilities and current or prior year losses have been taken into consideration even if discovered within the period after the date of the balance sheet and preparation of the financial statements;
all amounts of impairment and depreciation have been taken into consideration and calculated irrespective of whether the financial result was a loss or profit;
d) Income and expenses incurred during the reporting year have been taken into consideration irrespective of the payment date or date when the invoice was issued or received; Expenses were matched with revenue for the reporting period.
e)Assets and liabilities have been valued separately;
f)The opening balance agrees with the prior year closing balance.
g)All material items, which would influence the decision-making process of users of the financial statements, have been recognised and insignificant items have been combined and their details disclosed in the notes.
h) Business transactions are recorded taking into account their economic contents and substance, not the legal form.
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
15
Related parties
Related parties represent both legal entities and private individuals related to the company in accordance with the following rules.
a)A person or a close member of that person’s family is related to a reporting entity if that person:
i.has control or joint control over the reporting entity;
ii.has significant influence over the reporting entity; or
iii.is a member of the key management personnel of the reporting entity or of a parent of the reporting entity.
b) An entity is related to a reporting entity if any of the following conditions applies:
i.The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others);
ii.One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member);
iii.Both entities are joint ventures of the same third party;
iv.One entity is a joint venture of a third entity and the other entity is an associate of the third entity;
v.The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity.
vi.The entity is controlled, or jointly controlled by a person identified in (a);
vii.a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
viii. The entity or any member of the group to which the entity belongs provides management personnel services to the entity or the parent of company of the entity.
Related party transaction a transfer of resources, services or obligations between a reporting entity and a related party, regardless of whether a price is charged.
Financial instruments and financial risks
Financial instrument is an agreement that simultaneously results in financial assets of one party and financial liabilities of the other party.
The key financial instruments held by the Company are financial assets such as trade receivables, amounts due from related parties and other receivables, and financial liabilities such as prepayments from clients, accounts payable to suppliers and contractors and other creditors arising directly from its business activities.
Financial risks connected with the Company’s financial instruments, financial risk management
Key financial risks related to the Company’s financial instruments are:
Credit risk is the risk that the Company may incur financial losses if parties to the transactions fail to fulfil their liabilities under the contracts, and credit risk is primarily connected with trade receivables;
Currency risk– risk that the Company may suffer unexpected losses arising from fluctuations in the foreign exchange rates; the Company is not exposed to currency risk as it does not significant amounts of currencies other than EUR.
Interest rate risk risk that the Company may incur losses due to fluctuations in interest rates;
Liquidity risk – risk that the Company will not be able to meet its financial liabilities in due time.
Management has implemented procedures to control the key risks.
Credit risk
The inability of insurance companies and patients to pay for the services provided by the Company in due time and in full amount. Most of the services are paid for within a short period of time after the provision of services or are funded by state or insurance providers, so the credit risk is low.
Interest rate risk
Management believes that interest rate risk is not material.
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
16
Liquidity risk
The Company has no external loans and it has significant financial resources to settle its liabilities.
Fair value of financial assets and liabilities
Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm’s length transaction. Financial assets and financial liabilities are carried at cost which according to management approximates their fair value at acquisition plus any related additional expenses. Purchase costs are acquisition costs of goods or services (net of discounts received) with added additional costs related to the purchase.
Reporting period
The reporting period comprises the 12 months from 1 January 2022 to 31 December 2022.
Currency unit and revaluation of foreign currency
All amounts in these financial statements are expressed in the official currency of Latvia euro (EUR), the functional currency of the Company.
Foreign currency transactions are translated into EUR according to currency exchange rates effective at the date of transaction and determined by reconciliation of the system of the European Central Bank and other central banks and which is published on the website of the European Central Bank.
As at the reporting date, all monetary assets and liabilities are translated into EUR according to exchange rates published on the website of the European Central bank. Non-monetary items of assets and liabilities are revalued to euros in accordance with the reference exchange rate published by the European Central Bank on the transaction date.
Exchange rate per EUR 1:
31.12.202231.12.2021
USD1.06660 1.13260
Gain or loss resulting from payments under transactions executed in foreign currencies and the translation of monetary assets and liabilities denominated in foreign currencies is reflected in the profit and loss statement of the respective period.
Estimates and judgements
The preparation of financial statements requires the management to make judgements, estimates, and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expenses. The actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Changes in accounting estimates are recognized in the period when those estimates are reviewed and in future periods.
Key sources of estimation uncertainty are the following:
(i) Useful lives of fixed and intangible assets
Management estimates the useful lives of fixed and intangible assets in proportion to the expected duration of use of the asset (its expected capacity or effectiveness) based on historical experience with similar fixed assets and future plans. Land is not subject to depreciation. For other assets, depreciation and amortization is calculated on a straight-line basis over the entire useful life of the respective intangible asset and fixed asset in order to write their value or revalued value down to the estimated book value at the end of the useful life based on the following rates:
%
Intangible assets
20
Buildings and constructions
2.5 - 2.85
Communication equipment and instruments
33.33
Other fixed assets
20
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
17
Current maintenance and repair costs of fixed assets are recognized in the profit and loss statement as incurred.
(ii) Fixed asset valuation
Fixed assets other than land, buildings and constructions are carried at cost less accumulated depreciation and impairment losses.
Land, buildings and constructions are measured by the Company using the revaluation model. The balance sheet item Land, buildings and engineering structures of the financial statements of the Company is presented at revalued value, which equals fair value at the revaluation date net of subsequent accumulated deprecation and impairment loss.
Management has, as at 31 December 2020, carried out a valuation of the entire balance sheet item ‘Land, buildings and engineering structures’ and determined the carrying amounts of all land plots, buildings and engineering structures to be consistent with market value based on valuations by external certified appraisers. For details on the revaluation please refer to Note 8.
According to the policy, revaluation of a single building or construction requires the whole category to be revalued. To determine the impact of revaluation at the date of revaluation accrued depreciation is netted of cost or other value, which replaces cost in the financial statements, and the carrying amount is increased or decreased according to the revalued value of the building or structure in the following manner: depreciation accrued to the date of revaluation is initially written-off of the current carrying amount of fixed asset, and afterwards the residual value is increased or decreased according to the fair value of fixed asset as a result of revaluation.
In case the fair value of fixed assets at the balance sheet date is lower than their carrying amount, and such impairment is expected to be permanent, fixed assets are recognized at the lower value. The revaluation result is recognized in the profit and loss statement except where a previously recognized increase in the value of fixed assets offsets an impairment loss. In that event, the long term investment revaluation reserve is decreased by the amount of impairment.
In case the value of fixed assets at the balance sheet date is higher than the valuation on the balance sheet, fixed assets are revalued to the higher value if the increase in value may be assumed to be other than temporary. The increase in value resulting from revaluation is recognized under ‘Long term investment revaluation reserve’. If an increase in the value resulting from revaluation compensates for the impairment of the same fixed asset which was previously recognized as an expense in the profit and loss statement, then the increase resulting from revaluation is recognized as income in the profit and loss statement as incurred. The long term investment revaluation reserve is decreased when the revalued asset is disposed, is no longer utilized, or the increase of value is no longer reasonable.
The increase in value recognized in the long term investment revaluation reserve under equity is reversed by recognizing a decrease in the profit and loss statement upon liquidation or disposal of the revalued fixed asset.
(iii) Valuation of receivables
Receivables are disclosed at amortised cost net of impairment allowances. Doubtful debt allowances are recognized based on an individual management assessment of the recoverability of each receivable. Impairment allowances are recognized when objective evidence exists that the Company will not be able to recover the full amount of receivables according to the previously agreed repayment terms. The amount of allowance represents the difference between the carrying and recoverable amount of receivables. The allowance is charged to the profit and loss statement.
 
(iv) Provisions
Provisions are recognized when a past event has given rise to a present obligation or losses and the amount can be estimated reasonably. The likelihood of loss is assessed based on management assumptions. In order to determine the amount of loss management is required to select an appropriate calculation method and make specific assumptions connected with the specific risk. No provisions were made as at 31 December 2022.
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
18
Revenue recognition
Income from sales of goods
Revenue from the sales of goods is recognized in the profit and loss statement after the risks and rewards of ownership are transferred to the client.
No revenue is recognized if according to the provisions of the transaction the Company retains significant risks pertaining to the ownership of goods and the goods can be returned.
Income from services
Income from services provided is recognized in the profit and loss statement as generated. Income is received and recorded according to signed cooperation agreements.
Rental income
Rental income is recognised on a straight-line basis over the rental term.
Long and short term classification
Amounts with terms of receipt, payment or write off due in more than one year after the reporting date are classified as long term. Amounts to be received, paid or written off within a year are classified as short term.
Lease transactions
Operating lease (the Company as a Lessor)
The Company leases premises, which are part of revalued fixed assets. Depreciation is calculated on a straight-line basis over the entire useful life of the respective fixed asset in order to write its value down to the estimated carrying amount at the end of the useful life based on the rates set for similar fixed assets. Income from operating lease and client prepayments is charged to the profit and loss statement on a straight-line basis over the period of lease.
Operating lease – (the Company as a lessee)
Payments for operating lease are recognized in the profit and loss statement on a straight-line basis over the period of lease.
Fixed assets
All fixed assets other than land, buildings and constructions are recognised on the balance sheet at historical cost less depreciation.
For other assets, depreciation and amortization is calculated in accordance with the straight-line method over the entire useful life of the respective intangible assets and fixed assets in order to write their value or revalued value down to the estimated book value at the end of the useful life.
The depreciation method is reviewed at least on an annual basis, at the year-end.
Subsequent expenses are added to the book value of the asset or recognized as a separate asset only where it is highly probable that future benefits related to this item would flow into the company and expenses of this item can be estimated reliably. Such expenses are written off over the entire useful life of the respective asset. When capitalizing the costs of installed spare parts, the book value of the spare parts is written off in the profit and loss statement.
Profit or loss from disposal of fixed assets is calculated as the difference between the carrying amount of the asset and income generated from sale, and income from the reversal of the revaluation reserve of the respective fixed asset, and charged to the profit and loss statement as incurred.
Accounting and valuation of stock
Stock is carried at the lower of cost and net realizable value. Stock has been valued according to the FIFO method. Stock accounting is based on the perpetual method. Stock has been counted during the annual stock take.
Remuneration costs
Remuneration costs are determined in accordance with effective employment contracts, taking account of changing labour market requirements and trends. The application of certain principles is mutually agreed: per cent, fixed figures, individual conditions, combined conditions. Employees have access to the payroll procedures (data selection algorithms, data processing procedures, data flow organisation). The Company provides only short-term remuneration benefits to its employees.
AS Latvijas Jūras medicīnas centrs Financial statements for the 12-month period of 2022 Patversmes iela 23, Riga, LV-1005
Unified registration number: 40003306807
Notes to the financial statements
19
Donations
Grants received for special types of capital investments are treated as deferred income which is gradually recognised as revenue over the useful life of the fixed assets received or acquired using grants. Grants received to cover expenses are recognised in the same period when the related expenses have arisen, if all the conditions of receiving the grant are met.
Corporate income tax
(a) Current tax
On 1 January 2018 the Law on Enterprise Income Tax of the Republic of Latvia entered into force and set out a new regime for paying taxes. The tax rate is 20% from the taxable base determined by dividing the value of the amount taxable with corporate income tax by coefficient 0.8, includes:
distributed profit (dividends calculated, payments equivalent to dividends, conditional dividends), and
conditionally distributed profit (such as non-operating expenses and other specific cases provided for by the law).
The new tax regime is not